Competitive Advantages
Which advantages over its rivals hold up, and why are they hard to copy?
The Aerodynamic Separation Process is a stationary-wall centrifuge gaseous-diffusion process that uses proprietary flow directors to separate isotopes, and the Silicon-28 enrichment facility at Koedoespoort, Pretoria operates a 48-stage cascade. Quantum Enrichment applies precisely tuned laser-based isotope separation that exploits transition energies.
Together these technologies are designed to enable commercial-scale production of isotopes for nuclear medicine, semiconductor, and nuclear energy applications. They form the technical basis of a differentiated enrichment platform intended to strengthen supply chain access to critical materials.
Market Outlook
Is its category moving in its favor or against it?
ASP Isotopes targets three end markets for its enriched isotopes and related materials. In medical isotopes it is developing molybdenum-100, ytterbium-176, zinc-68, nickel-64, and carbon-14; in semiconductor materials it is advancing highly enriched silicon-28 produced from natural silane alongside depleted germanium-73; and through subsidiary Quantum Leap Energy it addresses nuclear fuels with HALEU, LEU+, and lithium-6 and lithium-7.
The company positions these markets around supply chain gaps in critical materials, with nuclear medicine demand supported by radiopharmaceutical growth and semiconductor demand tied to next-generation chip manufacturing. The Renergen acquisition adds helium and liquefied natural gas production serving industrial and technology customers.
Product Overview
What does the product do for its buyer, and how is it delivered?
ASP Isotopes enriches stable isotopes using its proprietary Aerodynamic Separation Process and Quantum Enrichment technologies, operating enrichment facilities in Pretoria, South Africa. The company sells enriched isotopes and related materials into nuclear medicine, semiconductor, and nuclear energy supply chains.
Its commercial offer centers on supplying critical materials, including medical isotopes and highly enriched silicon-28, while subsidiary Quantum Leap Energy addresses the nuclear fuel market. The acquired subsidiary Renergen adds helium and liquefied natural gas production to the group's revenue base.
